Home / Deep Research / Hepatic Fibrinogen Storage Disease

Hepatic Fibrinogen Storage Disease

Scanner Research Synthesis: Hepatic Fibrinogen Storage Disease (HFSD / HHHS)

2026-05-18
Scanner MONDO:0018060 Model: claude-opus-4-7

Scanner Research Synthesis: Hepatic Fibrinogen Storage Disease (HFSD / HHHS)

This report is a literature synthesis built strictly from the cached reference abstracts available in references_cache/ (PMID:33105716, PMID:31965886, PMID:36055263). No external deep-research provider was invoked; every statement below is grounded in one of these three cached sources, and PMIDs are cited inline. It is intended as a curation input for kb/disorders/Hepatic_Fibrinogen_Storage_Disease.yaml.

Disease Identity

  • Preferred name: Hepatic fibrinogen storage disease (HFSD); synonyms hereditary hypofibrinogenemia with hepatic storage (HHHS), fibrinogen storage disease (FSD) (PMID:33105716).
  • MONDO: MONDO:0018060 (congenital fibrinogen deficiency) used as the resolvable parent; the specific term MONDO:7770747 (hepatic fibrinogen storage disease) did not yet resolve in the released OAK sqlite cache at curation time.
  • Disease class: HFSD belongs to the ER storage diseases (ERSDs) — inborn errors of metabolism involving secretory proteins, characterized by hepatocellular storage in the rough ER and plasma deficiency of the relevant protein; ERSDs comprise alpha-1-antitrypsin, fibrinogen, and alpha-1-antichymotrypsin deficiencies (PMID:33105716).
  • Mechanistic contrast: Unlike simple Type I quantitative hypofibrinogenemia (a loss-of-function defect with a structurally normal liver), HFSD is a toxic gain-of-function disorder in which the mutant fibrinogen is assembled but secretion-incompetent, polymerizes, and aggregates spontaneously within the hepatocyte ER (PMID:33105716). The congenital fibrinogen disorders are formally classified by clottable and antigenic fibrinogen levels together with clinical phenotype and genotype (PMID:36055263).

Core Pathophysiology

Genetic mechanism

HFSD is caused by heterozygous missense mutations located exclusively in exons 8 and 9 of FGG (the fibrinogen γ-chain gene); eight FGG mutations had been reported at the time of the cached review, seven non-conservative missense substitutions plus one 14-nucleotide deletion activating a cryptic splice site (PMID:33105716). All affected residues lie in the highly conserved C-terminal globular γ module (residues ~310–401), and all mutations occur in the heterozygous state, supporting an autosomal dominant trait and indirectly suggesting homozygous lethality (PMID:33105716). Variants are named after the proband's city of origin (e.g., Aguadilla, Brescia, Angers, Beograd, Ankara, Pisa); Aguadilla is the most common worldwide (PMID:33105716; PMID:31965886).

Molecular cascade

  1. Mutant γ-chain production — destabilizing FGG γ-module missense variant produced in the heterozygous state (PMID:33105716).
  2. Hepatocellular ER aggregation — mutant fibrinogen retains polymerization ability but cannot be secreted, so it aggregates spontaneously within the rough ER of hepatocytes as densely packed tubular inclusions (PMID:33105716). A proposed structural mechanism invokes a serpin-like β-strand "pull-out" from the central β-sheet of the γ module, permitting polymerization of destabilized fibrinogen (PMID:33105716).
  3. Histologic inclusions — circular eosinophilic intracytoplasmic inclusion bodies, fibrinogen-immunoreactive, classified ultrastructurally into type I (fingerprint tubular), type II (ground-glass), and type III (mixed) deposits (PMID:33105716); a concrete case showed "circular eosinophil inclusion bodies in the hepato-cytoplasm" (PMID:31965886).
  4. ER stress / impaired proteostasis — accumulated polymers impose proteotoxic ER burden; autophagy is the main pathway for intracellular fibrinogen clearance, and defects in protein-degradation pathways are candidate disease modifiers (PMID:33105716).
  5. Hepatocyte injury — ER accumulation "strongly predisposes to the development of chronic liver disease of variable severity, both in children and adults" (PMID:33105716).
  6. Stellate-cell-mediated fibrogenesis — the injury/regeneration cycle drives hepatic fibrosis; patients show "tremendous variability in the severity of liver disease, going from no signs of injury, to mild/moderate liver fibrosis, up to cirrhosis" (PMID:33105716). The conserved TGF-beta/Smad mesenchymal-activation axis is modeled by conforms_to linkage to the fibrotic_response module.
  7. Secondary hypofibrinogenemia — retention rather than secretion lowers circulating fibrinogen; HFSD is defined by "hypofibrinogenemia, as well as the retention of variant fibrinogen within the hepatocellular endoplasmic reticulum" (PMID:31965886).

Key liver biology

Fibrinogen is a 340-kDa hexamer (two sets of Aα/Bβ/γ trimers) coded by FGA, FGB, FGG on chromosome 4q31.3, assembled in the ER (with calnexin/calreticulin and ERp57 chaperones) and mainly expressed in liver (PMID:33105716). In HFSD the liver is the principal target organ; the coagulopathy is secondary and clinically minor (PMID:33105716).

Clinical Phenotype

  • Elevated hepatic transaminases — usual presenting feature; HFSD "is associated with mild and intermittent hypertransaminasemia" (mean ALT 191 ± 119 U/L, AST 147 ± 97 U/L) (PMID:33105716); a case showed elevated ALT 122 IU/L and AST 119 IU/L (PMID:31965886).
  • Hypofibrinogenemia — defining laboratory feature, secondary to impaired secretion (PMID:33105716; PMID:31965886).
  • Hepatic fibrosis / cirrhosis — variable, from no injury through mild/moderate fibrosis up to cirrhosis, sometimes in children (PMID:33105716).
  • Hepatomegaly — "Abdominal ultrasonography showed mild hepatomegaly" in an asymptomatic 4-year-old (PMID:31965886).
  • Hypo-apo-β (APOB) proteinemia — "HHHS has been associated with hypo-apo-β (APOB) proteinemia in several cases", with fibrinogen and APOB co-accumulating in the same ER inclusions; the absence of APOB/MTTP mutations indicates a secondary phenomenon (PMID:33105716).
  • Coagulopathy without bleeding — "HHHS patients usually show prolonged coagulation parameters ... but no hemorrhagic manifestations nor abnormal wound healing" (PMID:33105716).
  • Onset — first symptoms (usually transaminase elevation) at a young age (mean 13.1 ± 20.2 years); HFSD equally distributed between sexes (PMID:33105716).

Disease Modifiers / Variable Expressivity

The same FGG mutation can behave differently across individuals, even within a family. Proposed modifiers: (i) genetic defects in protein-degradation / autophagy pathways governing mutant-fibrinogen clearance; (ii) xenobiotic intake (estrogen therapy, alcohol); (iii) acute/chronic viral infection and the acute-phase over-production of fibrinogen "crowding" an already burdened ER (PMID:33105716). This is a documented mechanistic theme not yet modeled as a discrete pathophysiology node and is a candidate enrichment.

Genetics Summary

Table (click to expand)
Gene HGNC Role Mutation class
FGG hgnc:3694 Causative Heterozygous missense in exons 8/9 (γ module, residues ~310–401); one cryptic-splice deletion (PMID:33105716)

Inheritance: Autosomal dominant; heterozygous only (PMID:33105716).

Treatment-relevant mechanisms

  • Carbamazepine (autophagy enhancer) + ursodeoxycholic acid — beneficial in some cases; CBZ is "known to enhance autophagy, and its efficacy seems to be related to the normalization of ALT levels" (PMID:33105716).
  • Supportive care / monitoring — fibrinogen supplementation is the cornerstone of bleeding management in fibrinogen disorders generally (PMID:36055263), but is only rarely required in HFSD given the minimal bleeding phenotype (PMID:33105716).
  • No HFSD-specific liver transplantation evidence is present in the cached abstracts (the prior PR review correctly flagged and removed an unsupported transplantation claim).

Content-Completeness Cross-Check vs. current YAML

Table (click to expand)
Dimension Status
Phenotype coverage Adequate after enrichment — transaminase elevation, hypofibrinogenemia, hepatic fibrosis, cirrhosis, hepatomegaly, hypo-APOB proteinemia, subclinical coagulopathy all modeled.
Subtype completeness Adequate — single mechanistic entity; FGG city-named alleles are variant-level, not subtypes.
Pathophysiology Adequate — mutant γ-chain → ER aggregation → ER stress/autophagy → hepatocyte injury → stellate-cell activation (conforms_to fibrotic_response#Mesenchymal Cell Activation) → excessive hepatic ECM deposition (conforms_to fibrotic_response#Excessive ECM Deposition) → fibrosis/cirrhosis; secondary hypofibrinogenemia → subclinical coagulation abnormality. Modifier-gene/autophagy-capacity theme is noted in notes and remains an optional future node.
Treatments Adequate — CBZ+UDCA and supportive care, both with exact cached-abstract snippets.
Genetic Adequate — FGG causative, exons 8/9, heterozygous dominant.
Biomarkers/diagnostics Description-level only (immunohistochemistry/electron microscopy diagnosis); not formalized as structured biomarkers — optional enrichment.
References Three cached PMIDs; all snippets are exact whitespace-normalized substrings.

Notes for reviewers

  • This artifact is a transparent scanner cached-reference synthesis, not an external provider narrative; it follows the same format as the sibling approved PR for Congenital Hypofibrinogenemia (#2727).
  • The conserved TGF-beta/Smad mesenchymal-activation evidence is intentionally not duplicated as a disease-specific snippet (the cached HFSD abstracts do not mention TGF-beta or stellate cells by name); it is inherited through conforms_to: fibrotic_response#Mesenchymal Cell Activation, mirroring the Wilson's Disease hepatic-fibrosis conformance pattern.
  • disease_term should be re-pointed from MONDO:0018060 to MONDO:7770747 once the OAK mondo cache refreshes (tracked in the entry notes).